All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
On Sunday 3rd June an oral abstract session took place at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract 7503 was presented by Olivier Casasnovas, CHU Le Bocage Service d’Hématologie Clinique, Dijon, on the AHL2011 phase III LYSA study (NCT01358747). This study compared early PET-driven treatment de-escalation to a not PET-monitored strategy in patients with previously untreated advanced Hodgkin lymphoma (HL).
The study aimed to assess whether interim PET could identify patients with a better outcome to be given de-escalation treatment after treatment with upfront BEACOPP. A total of 823 patients were randomized to the standard arm (n = 413) and the experimental arm (n = 410).
Dr. Casasnovas concluded that PET performed after 2 cycles of BEACOPPesc can be safely used to guide subsequent treatment that allows to reduce treatment-related toxicity in most patients with similar outcomes to standard treatment. See below for an interview with Dr Casasnovas where he describes the key outcomes and results of the study.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox